{
  "guideline": {
    "id": "PA166182738",
    "name": "Annotation of FDA Label for siponimod and CYP2C9",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 13,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182738",
    "relatedChemicals": [
      {
        "id": "PA166182736",
        "name": "siponimod",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312707",
      "name": "Recommendation Annotation PA166312707",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452219006,
        "html": "<p>&quot;Maintenance Dosage In patients with a CYP2C9 *1/*3 or *2/*3 genotype, after treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 1 mg taken orally once daily starting on Day 5.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312709",
      "name": "Recommendation Annotation PA166312709",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452219008,
        "html": "<p>&quot;Maintenance Dosage After treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 2 mg taken orally once daily starting on Day 6.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*2": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312711",
      "name": "Recommendation Annotation PA166312711",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452219010,
        "html": "<p>&quot;MAYZENT is contraindicated in patients who have [a] CYP2C9*3/*3 genotype.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312710",
      "name": "Recommendation Annotation PA166312710",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452219009,
        "html": "<p>&quot;Maintenance Dosage After treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 2 mg taken orally once daily starting on Day 6.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*2": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312708",
      "name": "Recommendation Annotation PA166312708",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452219007,
        "html": "<p>&quot;Maintenance Dosage After treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 2 mg taken orally once daily starting on Day 6.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 2.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166312706",
      "name": "Recommendation Annotation PA166312706",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182736",
          "name": "siponimod",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452219005,
        "html": "<p>&quot;Maintenance Dosage In patients with a CYP2C9 *1/*3 or *2/*3 genotype, after treatment titration (see Treatment Initiation), the recommended maintenance dosage of MAYZENT is 1 mg taken orally once daily starting on Day 5.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*1": 1.0,
          "*3": 1.0
        }
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product MAYZENT (siponimod), NDA209884, Novartis Pharmaceuticals Corporation",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209884"
    }
  ],
  "version": "2024-03-08-14-34"
}